Aurobindo Pharma Limited
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system,… Read more
Aurobindo Pharma Limited - Asset Resilience Ratio
Aurobindo Pharma Limited (AUROPHARMA) has an Asset Resilience Ratio of 16.92% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2025)
This chart shows how Aurobindo Pharma Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Aurobindo Pharma Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹88.91 Billion | 16.92% |
| Short-term Investments | ₹10.20 Million | 0.0% |
| Total Liquid Assets | ₹88.92 Billion | 16.92% |
Asset Resilience Insights
- Good Liquidity Position: Aurobindo Pharma Limited maintains a healthy 16.92% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Aurobindo Pharma Limited Industry Peers by Asset Resilience Ratio
Compare Aurobindo Pharma Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp Preferred
KO:000105 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma
KO:000220 |
Drug Manufacturers - Specialty & Generic | 1.74% |
|
Ildong Holdings Co Ltd
KO:000230 |
Drug Manufacturers - Specialty & Generic | 1.57% |
Annual Asset Resilience Ratio for Aurobindo Pharma Limited (2004–2025)
The table below shows the annual Asset Resilience Ratio data for Aurobindo Pharma Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 11.15% | ₹55.52 Billion | ₹497.85 Billion | -0.04pp |
| 2024-03-31 | 11.19% | ₹50.43 Billion | ₹450.72 Billion | -0.24pp |
| 2023-03-31 | 11.42% | ₹45.57 Billion | ₹398.90 Billion | +8.38pp |
| 2022-03-31 | 3.05% | ₹10.33 Billion | ₹339.22 Billion | +2.31pp |
| 2021-03-31 | 0.73% | ₹2.48 Billion | ₹338.54 Billion | +0.02pp |
| 2020-03-31 | 0.71% | ₹2.06 Billion | ₹289.28 Billion | -0.55pp |
| 2019-03-31 | 1.26% | ₹3.33 Billion | ₹264.54 Billion | +0.89pp |
| 2018-03-31 | 0.37% | ₹773.90 Million | ₹211.01 Billion | +0.08pp |
| 2017-03-31 | 0.29% | ₹470.00 Million | ₹162.49 Billion | +0.23pp |
| 2016-03-31 | 0.06% | ₹98.70 Million | ₹159.20 Billion | -0.09pp |
| 2015-03-31 | 0.15% | ₹196.50 Million | ₹129.14 Billion | +0.15pp |
| 2014-03-31 | 0.00% | ₹300.00K | ₹94.90 Billion | 0.00pp |
| 2013-03-31 | 0.00% | ₹400.00K | ₹72.78 Billion | -0.30pp |
| 2012-03-31 | 0.30% | ₹186.80 Million | ₹62.38 Billion | +0.30pp |
| 2011-03-31 | 0.00% | ₹400.00K | ₹58.72 Billion | 0.00pp |
| 2008-03-31 | 0.00% | ₹600.00K | ₹36.34 Billion | +0.00pp |
| 2007-03-31 | 0.00% | ₹500.00K | ₹35.06 Billion | 0.00pp |
| 2006-03-31 | 0.00% | ₹500.00K | ₹26.89 Billion | +0.00pp |
| 2005-03-31 | 0.00% | ₹300.00K | ₹21.30 Billion | 0.00pp |
| 2004-03-31 | 0.00% | ₹300.00K | ₹18.66 Billion | -- |